Russia’s Pharmasynthez Forecasts 50% Growth To $150 Million By 2015
This article was originally published in PharmAsia News
Executive Summary
Pharmasynthez, a Russian drug maker that acts as an intermediary between Indian and Russian drug firms, eyes a 50% increase in business by 2015, to $150 million.